104 related articles for article (PubMed ID: 20561353)
21. Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens.
Berntorp E
Haemophilia; 2009 Nov; 15(6):1219-27. PubMed ID: 19659939
[TBL] [Abstract][Full Text] [Related]
22. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
23. An approach to target joint bleeding in hemophilia: prophylaxis for all or individualized treatment?
Abshire T
J Pediatr; 2004 Nov; 145(5):581-3. PubMed ID: 15520752
[No Abstract] [Full Text] [Related]
24. Assessment of haemophilia treatment practice pattern in Japan.
Ono O; Suzuki Y; Yosikawa K; Wada I; Doi Y; Takano M; Wada Y; Fukushima K;
Haemophilia; 2009 Sep; 15(5):1032-8. PubMed ID: 19476508
[TBL] [Abstract][Full Text] [Related]
25. Treatment of hemophilia B with a new clotting-factor concentrate.
Hoag MS; Johnson FF; Robinson JA; Aggeler PM
N Engl J Med; 1969 Mar; 280(11):581-6. PubMed ID: 5764825
[No Abstract] [Full Text] [Related]
26. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
[TBL] [Abstract][Full Text] [Related]
27. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
28. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
29. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
30. Unresolved issues in prophylaxis.
Brown SA; Aledort LM; Astermark J; Berntorp E; van den Berg M; Blanchette V; Donfield S; Gringeri A; Hilgartner M; Kulkarni R; Leissinger C; Negrier C; Nuss R; Petterson H; Petrini P; Poulios N; Schramm W;
Haemophilia; 2002 Nov; 8(6):817-21. PubMed ID: 12410654
[No Abstract] [Full Text] [Related]
31. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
32. Cardiac surgery in patients with haemophilia B: a case report and review of the literature.
Krakow EF; Walker I; Lamy A; Anderson JA
Haemophilia; 2009 Jan; 15(1):108-13. PubMed ID: 18976256
[TBL] [Abstract][Full Text] [Related]
33. [Possibilities of self-treatment in hemophilias. Preliminary report].
Göbel U; Schulz RD
Dtsch Med Wochenschr; 1972 Sep; 97(37):1376-9. PubMed ID: 5055724
[No Abstract] [Full Text] [Related]
34. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
[TBL] [Abstract][Full Text] [Related]
35. Home treatment of haemophilia and Christmas disease: five years' experience.
Rizza CR; Spooner RJ
Br J Haematol; 1977 Sep; 37(1):53-66. PubMed ID: 588479
[No Abstract] [Full Text] [Related]
36. Haemophilia B: Christmas disease.
Giangrande P
Expert Opin Pharmacother; 2005 Aug; 6(9):1517-24. PubMed ID: 16086639
[TBL] [Abstract][Full Text] [Related]
37. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of prophylactic replacement therapy in haemophilia B.
Morfini M; Mannucci PM; Mariani G; Panicucci F; Petrucci F; Baicchi U; Capitanio A; Ferrini PL; Mandelli F
Scand J Haematol; 1976 Jan; 16(1):41-7. PubMed ID: 1251139
[TBL] [Abstract][Full Text] [Related]
39. Feasibility of prophylaxis and immune tolerance induction regimens in haemophilic children using fully implantable central venous catheters.
Mancuso ME; Mannucci PM; Sartori A; Agliardi A; Santagostino E
Br J Haematol; 2008 May; 141(5):689-95. PubMed ID: 18410458
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with a Swedish factor IX concentrate.
Nilsson IM; Ahlberg A; Björlin G
Acta Med Scand; 1971 Oct; 190(4):257-66. PubMed ID: 5137259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
